Content HUBWith a range of interviews, industry analysis, insights and opinions, Oxford Global's Content Hub brings you the latest in Life Science research
Video Q&A
In Converstion with Theodore Alexandrov, Team Leader at the European Molecular Biology Laboratory
19 May 2022
Written Q&A
Gábor Balázsi, Henry Laufer Professor of Physical and Quantitative Biology at Stony Brook University, takes us through the most valuable features that NextGen Omics US brought us in 2022.
18 May 2022
Commentary
This Commentary article investigates the potential applications of digital twins in refining the developmental timeline for drug substance development. Capturing and conserving the understanding from ongoing processes allows researchers to learn more about the intricacies of the developmental process more rapidly.
17 May 2022
Commentary
In this Commentary article, we investigate the application of new research techniques to inspecting genomic data for the presence of de novo variants - genetic alterations present for the first time in one individual as a result of a variant inherited from a parent. Used in combination with data from the 100,000 Genome Project, these techniques could reduce the time taken for patients to receive a diagnosis for rare genetic diseases.
16 May 2022
Insight Article
From maximising immune response with combination biomarkers to conducting diagnostic innovation in immunotherapy prognosis, the future of predictive biomarkers is fast approaching. We speak to senior representatives from industry and academia to find out more.
16 May 2022
Whitepaper
Biomarkers come in many shapes and sizes. It’s an ever-evolving subject with many under-discovered possibilities. Let’s look at some ways biomarkers are looking to evolve.
13 May 2022
Whitepaper
Discovering a strong biomarker is an expensive and time-consuming process. One of the key takeaways is to take your time and look at the data before you start testing for biomarkers.
13 May 2022
Commentary
A Senior Director at AstraZeneca takes us through how the company synthesises and validates novel PROTACs.
13 May 2022
Whitepaper
Three key take aways when you develop biomarkers: one during biomarker discovery, one during biomarker development and one during biomarker validation.
13 May 2022
Insight Article
UCB, Bicycle Therapeutics, and Sanofi share their latest findings in Peptide discovery at Biologics UK 2022.
10 May 2022
Webinar
Rebus Biosystems has assembled five collaborators to share aspects of their cellular examinations of the human brain. From new strides in understanding brain development to exploring the sub cellular details of disease, these presentations illustrate the array of knowledge gained through cellular spatial exploration.
09 May 2022
Insight Article
mRNA took a long time to come to fruition, but recent advancements has enabled production at a never seen before scale.
06 May 2022
Discussion Group Report
This month’s discussion was led by Pieter van der Velden. Topics included improving multiplex assays, T-Cell quantification and DNA methylation.
05 May 2022
Discussion Group Report
Digital health is often seen as the 'next big thing' but there are challenges ahead. This month, our discussion group focused on fragmentation, data flow, protection and regulatory approval.
05 May 2022
Video Q&A
Video Interview | Namir Hassan, CEO at Zelluna Immunotherapy
05 May 2022
Discussion Group Report
Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our April Discussion Group addressing ‘Accelerating Antibody Engineering With AI/ML & Advanced Computational Tools and Technologies’ brought together an exclusive panel of key opinion leaders to address the market’s growth and future outlook.
05 May 2022
Insight Article
Single-cell proteomics has developed quickly, despite being a relatively new field. NanoPOTS and FACS are being used to improve proteome coverage and minimise sample size.
05 May 2022
Insight Article
Despite their advantages, combination products present new technological and organizational challenges. They require new product development strategies compared to standalone products, drugs, and devices.
05 May 2022

We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.

Contact Us:

Copyright Oxford Global Marketing Limited. All rights reserved.